Epizyme Inc (NASDAQ:EPZM) CFO Paolo Tombesi sold 1,805 shares of the firm’s stock in a transaction on Friday, June 26th. The shares were sold at an average price of $16.15, for a total transaction of $29,150.75. Following the transaction, the chief financial officer now directly owns 23,747 shares of the company’s stock, valued at approximately $383,514.05. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.
Shares of Epizyme stock traded down $0.30 during trading on Tuesday, hitting $15.95. The company’s stock had a trading volume of 5,263 shares, compared to its average volume of 1,823,567. Epizyme Inc has a 52 week low of $9.73 and a 52 week high of $27.82. The company has a fifty day simple moving average of $17.89 and a two-hundred day simple moving average of $19.66. The company has a market capitalization of $1.64 billion, a PE ratio of -7.90 and a beta of 2.05. The company has a debt-to-equity ratio of 0.22, a quick ratio of 14.74 and a current ratio of 14.81.
Epizyme (NASDAQ:EPZM) last announced its quarterly earnings results on Monday, May 4th. The biopharmaceutical company reported ($0.51) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.74) by $0.23. The firm had revenue of $1.35 million for the quarter, compared to the consensus estimate of $2.63 million. Epizyme had a negative net margin of 1,111.58% and a negative return on equity of 67.19%. As a group, analysts predict that Epizyme Inc will post -2.37 EPS for the current year.
A number of equities analysts recently weighed in on the stock. Oppenheimer reissued a “hold” rating and set a $17.00 target price (up previously from $16.00) on shares of Epizyme in a research note on Tuesday, May 5th. Morgan Stanley lifted their price objective on shares of Epizyme from $28.00 to $31.00 and gave the company an “overweight” rating in a report on Friday, June 19th. ValuEngine upgraded shares of Epizyme from a “hold” rating to a “buy” rating in a report on Thursday, April 2nd. BidaskClub lowered shares of Epizyme from a “hold” rating to a “sell” rating in a research report on Wednesday, June 3rd. Finally, SVB Leerink lowered their price objective on shares of Epizyme from $18.00 to $16.00 and set a “market perform” rating on the stock in a research report on Friday, June 19th. Two research analysts have rated the stock with a sell rating, two have given a hold rating and seven have given a buy rating to the stock. Epizyme presently has a consensus rating of “Hold” and an average target price of $27.22.
Epizyme, Inc, a late-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases primarily in the United States. The company's lead products candidate is tazemetostat, an inhibitor of the EZH2 histone methyltransferase, which is in the Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function; and Phase II clinical trial for adults and Phase I clinical trial for children with epithelioid sarcoma and other INI1-negative solid tumors.
See Also: What is a management fee?
Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with MarketBeat.com's FREE daily email newsletter.